247050-23-3

Usage

Uses

Used in Pharmaceutical Industry:
3-(FLUOROMETHYL)-1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONYL CHLORIDE is used as a key intermediate for the synthesis of pharmaceuticals, due to its ability to be incorporated into complex chemical structures, enhancing the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
3-(FLUOROMETHYL)-1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONYL CHLORIDE is used as a precursor in the production of agrochemicals, leveraging its reactivity to create compounds that can be employed in the development of pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Medicinal Chemistry Research:
3-(FLUOROMETHYL)-1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONYL CHLORIDE is utilized as a valuable building block in medicinal chemistry research for the design and synthesis of novel bioactive molecules, potentially leading to the discovery of new therapeutic agents.

InChI:InChI=1/C10H9ClFNO3S/c11-17(15,16)8-2-1-6-3-7(5-12)13-10(14)9(6)4-8/h1-2,4,7H,3,5H2,(H,13,14)

Upstream product

• 245107-67-9 (+/-)-methyl N-(1-fluoro-3-phenylprop-2-yl)carbamate 
• 247050-21-1 (+/-)-3-fluoromethyl-3,4-dihydroisoquinolin-1(2H)-one 

Downstream Products

• 247050-29-9 (+/-)-3-fluoromethyl-7-[N-(4-chlorophenyl)aminosulfonyl]-3,4-dihydroisoquinolin-1(2H)-one 
• 247050-26-6 (+/-)-7-aminosulfonyl-3-fluoromethyl-3,4-dihydroisoquinolin-1(2H)-one 
• 247050-28-8 (+/-)-3-fluoromethyl-7-(N-benzylaminosulfonyl)-3,4-dihydroisoquinolin-1(2H)-one 

Relevant academic research and scientific papers

Synthesis and biochemical evaluation of 3-fluoromethyl-1,2,3,4- tetrahydroisoquinolines as selective inhibitors of phenylethanolamine N- methyltransferase versus the α2-adrenoceptor

A series of 3-fluoromethyl-1,2,3,4-tetrahydroisoquinolines (3- fluoromethyl-THIQs) was proposed, and their phenylethanolamine N- methyltransferase (PNMT) and α2-adrenoceptor affinities were predicted through the use of comparative molecular field analysis (CoMFA) models. These compounds were synthesized and evaluated for affinity at PNMT and the α2- adrenoceptor. It was discovered that these compounds are some of the most selective inhibitors of PNMT versus the α2-adrenoceptor known. To determine the ability of these compounds to penetrate the blood-brain barrier (BBB), a series of THIQs possessing a variety of calculated partition coefficients (Clog P) were assayed using an in vitro BBB model. This study found a good correlation between lipophilicity (Clog P) and BBB permeability, which indicated that THIQs possessing Clog P values of at least 0.13-0.57 should have some penetration into the brain. Two compounds [3-fluoromethyl-7-N-(4- chlorophenyl)aminosulfonyl-THIQ (18) and 3-fluoromethyl-7-cyano-THIQ (20)] possess calculated partition coefficients greater than 0.57 and display selectivities (α2-adrenoceptor K/PNMT K1) greater than 200 and thus represent promising leads in the development of highly selective inhibitors of PNMT with the ability to penetrate the BBB.